(Q38027568)

27 August 2017

title

Personalized medicine policy challenges: measuring clinical utility at point of care (English)

1 reference

27 August 2017

main subject

personalized medicine

1 reference

Tibor van Rooij

1

1 reference

27 August 2017

Donna M Wilson

series ordinal

2

1 reference

27 August 2017

Sharon Marsh

series ordinal

3

1 reference

27 August 2017

publication date

1 June 2012

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

289-295

1 reference

Pharmacogenomics--drug disposition, drug targets, and side effects

27 August 2017

cites work

1 reference

Improving oncology outcomes through targeted therapeutics will require electronic delivery systems

21 January 2018

1 reference

Comparative effectiveness research and personalized medicine: catalyzing or colliding?

21 January 2018

1 reference

Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine

21 January 2018

1 reference

Pharmacogenetics in Europe: barriers and opportunities

21 January 2018

1 reference

Emerging landscape of genomics in the Electronic Health Record for personalized medicine

21 January 2018

1 reference

Genetic warfarin dosing: tables versus algorithms.

21 January 2018

1 reference

A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine

21 January 2018

1 reference

Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab

21 January 2018

1 reference

Market uptake of biologic and small-molecule--targeted oncology drugs in Europe

21 January 2018

1 reference

Health technology assessment in the era of personalized health care

21 January 2018

1 reference

A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study.

21 January 2018

1 reference

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 January 2018

1 reference

Génome Québec & Montreal Heart Institute Pharmacogenomics Centre: a translational pharmacogenomics platform--from R&D to the clinic

21 January 2018

1 reference

Integrating pharmacogenomics into pharmacy practice via medication therapy management

21 January 2018

1 reference

Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

21 January 2018

1 reference

Comparative effectiveness research and genomic medicine: an evolving partnership for 21st century medicine

21 January 2018

1 reference

Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine

21 January 2018

1 reference

Can pharmacogenomics improve malaria drug policy?

21 January 2018

1 reference

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

21 January 2018

1 reference

Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses

21 January 2018

1 reference

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues

21 January 2018

1 reference

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer

21 January 2018

1 reference

The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

Molecular targets for breast cancer therapy and prevention

21 January 2018

1 reference

HER2-positive breast cancer: current and future treatment strategies

21 January 2018

1 reference

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

Trastuzumab: triumphs and tribulations

21 January 2018

1 reference

Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer

21 January 2018

1 reference

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

21 January 2018

1 reference

Irinotecan pharmacogenomics

21 January 2018

1 reference

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

21 January 2018

1 reference

Irinotecan pharmacogenetics: influence of pharmacodynamic genes

21 January 2018

1 reference

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein

21 January 2018

1 reference

Trastuzumab beyond progression: a cost-utility analysis.

21 January 2018

1 reference

Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.

21 January 2018

1 reference

Genomic testing and therapies for breast cancer in clinical practice.

21 January 2018

1 reference

Do economic evaluations of targeted therapy provide support for decision makers?

21 January 2018

1 reference

Bridging trial and decision: a checklist to frame health technology assessments for resource allocation decisions.

21 January 2018

1 reference

Valuing pharmacogenetic testing services: A comparison of patients' and health care professionals' preferences

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERP.12.15

1 reference

27 August 2017

1 reference